Literature DB >> 1558779

Acute lymphoblastic leukemia and Klinefelter's syndrome.

M P Shaw1, O B Eden, E Grace, P M Ellis.   

Abstract

We report two children with acute lymphoblastic leukemia (ALL) who in initial cytogenetic investigation were coincidently found to have a 47, XXY karyotype. In one patient 100% of peripheral blood lymphocytes showed a 47,XXY complement, but in the other only 30% of cells had such a complement, the remainder having a normal male karyotype (46, XY). In neither case was the diagnosis of Klinefelter's syndrome clinically obvious. Antileukemic therapy may exacerbate both the hypogonadism and the learning difficulties seen in this condition. Routine cytogenetic investigations on peripheral blood and bone marrow should be performed in all new cases of leukemia. Cytogenetic analysis of cultured fibroblasts is essential in all cases in which the abnormal X line did not disappear after initial therapy. Evidence of an increased risk of leukemia in association with Klinefelter's is beginning to accumulate.

Entities:  

Mesh:

Year:  1992        PMID: 1558779     DOI: 10.3109/08880019209006400

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

1.  Congenital Aneuploidy in Klinefelter Syndrome with B-Cell Acute Lymphoblastic Leukemia Might Be Associated with Chromosomal Instability and Reduced Telomere Length.

Authors:  Eigil Kjeldsen
Journal:  Cancers (Basel)       Date:  2022-05-06       Impact factor: 6.575

2.  Clinical case of acute myeloblastic leukemia with t(8;21)(q22;q22) in a patient with Klinefelter's syndrome.

Authors:  Vanya Slavcheva; Tzvetan Lukanov; Gueorgui Balatsenko; Svetlana Angelova; Antonio Antonov; Lachezar Bogdanov; Nikolay Tsvetkov
Journal:  Hematol Rep       Date:  2010-12-22

3.  Cancer incidence in men with Klinefelter syndrome.

Authors:  H Hasle; A Mellemgaard; J Nielsen; J Hansen
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.